pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

282 catalysts · 4,779 phase readout · 2,366 8k filing · 285 earnings · 271 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 27 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: filing×type: recall×type: pdufa×clear all
type
  • phase readout4,779
  • 8k filing2,366
  • earnings285
  • pdufa271
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Infectious Disease6
    • Ophthalmology5
    • Dermatology1
    • Oncology1
    • Pulmonology1

    Week of Apr 20, 2026

    2
    ›Apr 24, 2026drug expiry91d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry91d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata

    Week of Apr 27, 2026

    13
    ›Apr 27, 2026pdufa88d agoRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)dupilumab

    Therapy area: Dermatology. Indication: Chronic Urticaria

    full page →dupilumab →source: globaldata
    ›Apr 28, 2026drug expiry

    Week of Jun 1, 2026

    35
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d ago
    ← prev
    page 1 of 6
    next →
    87d ago
    GSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa87d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 29, 2026pdufa86d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoSarepta Therapeutics Inc — golodirsen (NDA/BLA Filing (US))golodirsen

    Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy

    full page →golodirsen →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026pdufa85d agoAxsome Therapeutics Inc — (bupropion hydrochloride + dextromethorphan) ER (PDUFA)(bupropion hydrochloride + dextromethorphan) ER

    Therapy area: Central Nervous System. Indication: Dementia Associated With Alzheimer's Disease

    full page →(bupropion hydrochloride + dextromethorphan) ER →source: globaldata
    Test PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    ›Jun 1, 2026pdufa53d agoTest PDUFA

    No description on file. Bork keeps sniffing.

    full page →source: test
    $REGN651.91+0.11%
    $GSK50.80+0.07%
    $MRK130.48+2.36%
    $SRPT15.88+0.38%
    $SNY43.36-0.98%
    $AXSM241.53+0.80%